Literature DB >> 28452194

Proteomic profiling identifies novel circulating markers associated with bronchiectasis in cystic fibrosis.

Emily M DeBoer1, Miranda E Kroehl2, Brandie D Wagner1,2, Frank J Accurso1, J Kirk Harris1, David A Lynch3, Scott D Sagel1, Robin R Deterding1.   

Abstract

PURPOSE: Evaluate bronchiectasis change over 1 year in children with cystic fibrosis (CF) and find blood proteins associated with bronchiectasis. EXPERIMENTAL
DESIGN: Pilot study of CF children who had chest computed tomography (CT) scans and blood collected during times of clinical stability. Blood plasma was analyzed for 1129 proteins using SOMAmer®, the SOMAscan proteomics platform. Bronchiectasis was measured on two CT scans collected 1 year apart. Spearman's rank estimated the correlations between outcomes. Clinical relevance was defined as |r| >0.40.
RESULTS: There were 26 children included: mean age 11.3 years (SD 2.4 years), mean Brody Bronchiectasis score 0.65 (SD 0.83), mean airway count 14.3 (SD 5.7) per CT slice. Brody bronchiectasis change over 1 year ranged from -1.0 to 1.9 and airway count change over one year ranged from -7.7 to 13.5 airways per slice. Proteins related to inflammation and extracellular matrix degradation were associated with cross-sectional and longitudinal structural changes. CONCLUSIONS AND CLINICAL RELEVANCE: Imaging outcomes were more strongly correlated with circulating proteins than age or spirometry values. The unique SOMAscan proteomic platform identifies several novel proteins in blood that are associated with bronchiectasis and that may serve as clinically useful biomarkers in children with CF.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Cystic fibrosis; Extracellular matrix; Lung Injury

Mesh:

Substances:

Year:  2017        PMID: 28452194     DOI: 10.1002/prca.201600147

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  3 in total

1.  Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.

Authors:  Jordana E Hoppe; Brandie D Wagner; J Kirk Harris; Steven M Rowe; Sonya L Heltshe; Emily M DeBoer; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2022-04-16       Impact factor: 5.527

Review 2.  Chemical Modification of Aptamers for Increased Binding Affinity in Diagnostic Applications: Current Status and Future Prospects.

Authors:  Jan P Elskens; Joke M Elskens; Annemieke Madder
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

3.  Large-scale plasma proteomics can reveal distinct endotypes in chronic obstructive pulmonary disease and severe asthma.

Authors:  Masaru Suzuki; John J Cole; Satoshi Konno; Hironi Makita; Hiroki Kimura; Masaharu Nishimura; Rose A Maciewicz
Journal:  Clin Transl Allergy       Date:  2021-12       Impact factor: 5.871

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.